SFX by Ex Libris Inc.

Title:	Location Matters: Site of Conjugation Modulates Stability and Pharmacokinetics of Antibody Drug Conjugates
Source:	Chemistry & biology [1074-5521] Strop, Pavel yr:2013

Basic

Sorry, no full text available...

Please use the document delivery service (see below)

Holding information

Holdings in library search engine ALBERT

Document delivery

Request document via Library/Bibliothek

Users interested in this article also expressed an interest in the following:
description	1.	Janthur, W.-D. D. "Drug conjugates such as antibody drug conjugates (ADCs), immunotoxins and immunoliposomes challenge daily clinical practice." International journal of molecular sciences 13.12 (2012): 16020-16795.
description	2.	Shani, J. "Preparation and control of radiopharmaceuticals in hospitals." Journal of radioanalytical chemistry 62.1 (1981): 291-.
description	3.	Tatsukawa, K. "Role of Transglutaminase 2 in Liver Injury via Cross-linking and Silencing of Transcription Factor Sp1." Gastroenterology 136.5 (2009): 1783-1795.
description	4.	Hamblett, Kevin J. "Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate." Clinical cancer research 10.20 (2004): 7063-7070.
description	5.	Bhattacharyya, R. "Disulfide bonds, their stereospecific environment and conservation in protein structures." Protein engineering, design & selection 17.11 (2004): 795-808.
description	6.	BLATTLER, W. "IMMUNOCONJUGATES CONTAINING NOVEL MAYTANSINOIDS - PROMISING ANTICANCER DRUGS." Cancer research 52.1 (1992): 127-131.
description	7.	Junutula, J. "Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index." Nature biotechnology 26.8 (2008): 925-932.
description	8.	"RN927C, a potent site-specific Trop-2 antibody-drug-conjugate (ADC) for treatment of solid tumors." Cancer research. 74.19.
description	9.	Xia, J. "Site-selective covalent reactions on proteinogenic amino acids." Current opinion in biotechnology 48 (2017): 220-227.
description	10.	Krall, N. "Site-selective protein-modification chemistry for basic biology and drug development." Nature chemistry 8.2 (2015): 103-113.
description	11.	Tumey LN, Manoj N. "Mild Method for Succinimide Hydrolysis on ADCs: Impact on ADC Potency, Stability, Exposure, and Efficacy." Bioconjugate chemistry 25.10 (2014): 1871-1880.
description	12.	Law, Scott C. "A Potent Anti-CD70 Antibody–Drug Conjugate Combining a Dimeric Pyrrolobenzodiazepine Drug with Site-Specific Conjugation Technology." Bioconjugate chemistry 24.7 (2013): 1256-1263.
description	13.	Kalyankar, Tukaram M. "CANCER VACCINE EMERGING TREATMENT: PRESENT AND FUTURE PROSPECTIVES." Asian Journal of Pharmaceutical and Clinical Research (2012): 33-.
description	14.	Tuma, Rabiya S. "Enthusiasm for antibody-drug conjugates." Journal of the National Cancer Institute 103.20 (2011): 1493-1494.
description	15.	Kadambi, Iyer J. "Antibody drug conjugates - Trojan horses in the war on cancer." Journal of pharmacological and toxicological methods 64.3 (2011): 207-212.
description	16.	Thornton, J M M. "Protein motifs and data-base searching." Trends in biochemical sciences 14.7 (1989): 300-304.
description	17.	Harapanhalli, Ravi S. "Food and Drug Administration Requirements for Testing and Approval of New Radiopharmaceuticals." Seminars in Nuclear Medicine 40.5 (2010): 364-384.
description	18.	von Minckwitz, G. "Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas." Breast cancer research 7.5 (2005): -26.
description	19.	Poznanovic, M. "PARP-1 Expression in the Mouse is Controlled by an Autoregulatory Loop: PARP-1 Binding to an Upstream S/MAR Element and to a Novel Recognition Motif in its Promoter Suppresses Transcription." Journal of molecular biology 388.4 (2009): 730-750.
description	20.	Tejuca, M. "Construction of an immunotoxin with the pore forming protein StI and ior C5, a monoclonal antibody against a colon cancer cell line." International immunopharmacology 4.6 (2004): 731-744.